GlassScriptPhysician profile
Steven J Price
NPI 1457302432
$1,288.61
in general payments reported to CMS, 2019-2025
30 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $54.48 · 2021: $150 · 2022: $129 · 2023: $92.06 · 2024: $285 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $170.83 | 2019-2025 | |
| Emd Serono, INC. | $124.90 | 2019 | |
| Amgen INC. | $123.90 | 2019 | |
| Sk Life Science, INC. | $77.97 | 2023-2024 | |
| Ucb, INC. | $68.66 | 2019-2024 | Briviact |
| Acorda Therapeutics, INC | $56.19 | 2019-2024 | Inbrija |
| Abbvie INC. | $53.76 | 2023-2025 | |
| Kyowa Kirin, INC. | $45.35 | 2024 | Nourianz |
| Lundbeck LLC | $43.64 | 2022 | |
| Tanabe Pharma America, INC. | $40.59 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $37.28 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $35.84 | 2019-2025 | Ultomiris |
| Genentech USA, INC. | $35.34 | 2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Pfizer INC. | $34.85 | 2024-2025 | |
| Biogen, INC. | $29.38 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $24.94 | 2021 | |
| Mdd US Operations, LLC | $23.55 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.47 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.73 | 2022 | |
| Argenx US, INC. | $22.64 | 2024 | Vyvgart |
| Abbott Laboratories | $22.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.10 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.04 | 2023 | Nuedexta |
| Bausch Health US, LLC | $20.31 | 2019 | |
| Amneal Pharmaceuticals LLC | $19.87 | 2024 | Ongentys |
| Eisai INC. | $19.67 | 2024 | |
| Acadia Pharmaceuticals INC | $18.29 | 2019 | |
| Medtronic, INC. | $18.10 | 2024 | Percept PC Brainsense |
| Teva Pharmaceuticals USA, INC. | $17.34 | 2022 | |
| Lilly USA, LLC | $13.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.